^
    1d
    KEYNOTE-585 China Extension study: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension (clinicaltrials.gov)
    P3, N=115, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: May 2024 --> Jun 2025
    Trial completion date
    |
    Keytruda (pembrolizumab) • cisplatin • docetaxel • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium
    1d
    Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (clinicaltrials.gov)
    P3, N=1007, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jun 2024 --> Jun 2025
    Trial completion date
    |
    Keytruda (pembrolizumab) • cisplatin • docetaxel • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium
    1d
    Effect of immune-modulating metronomic capecitabine as an adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma. (PubMed, BMC Immunol)
    Metronomic capecitabine chemotherapy was observed to induce an immunomodulatory effect in LA-NPC.
    Journal • Metastases
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    capecitabine
    2d
    Feasibility of the Maastro Applicator in Rectal Cancer (clinicaltrials.gov)
    P=N/A, N=10, Not yet recruiting, Maastricht Radiation Oncology | Trial completion date: Sep 2030 --> Apr 2031 | Initiation date: Dec 2023 --> Jul 2024 | Trial primary completion date: Sep 2025 --> Apr 2026
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    capecitabine
    2d
    Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors (clinicaltrials.gov)
    P1/2, N=63, Active, not recruiting, Centre Oscar Lambret | Suspended --> Active, not recruiting | N=102 --> 63
    Enrollment closed • Enrollment change • Combination therapy
    |
    Opdivo (nivolumab) • capecitabine • cyclophosphamide • vinblastine
    2d
    MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov)
    P2, N=1044, Completed, Hoffmann-La Roche | N=609 --> 1044
    Enrollment change • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab) • Erbitux (cetuximab) • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • 5-fluorouracil • Perjeta (pertuzumab) • Cotellic (cobimetinib) • capecitabine • oxaliplatin • leucovorin calcium
    5d
    A phase I/II study of nintedanib and capecitabine for refractory metastatic colorectal cancer. (PubMed, JNCI Cancer Spectr)
    The combination of nintedanib and capecitabine is well tolerated. Clinical efficacy appears to be superior to regorafenib or tipiracil hydrochloride monotherapy. Further investigation of similar combinations is warranted.
    P1/2 data • Clinical Trial,Phase I • Clinical Trial,Phase II • Journal • Metastases
    |
    SPP1 (Secreted Phosphoprotein 1)
    |
    Avastin (bevacizumab) • capecitabine • Stivarga (regorafenib) • nintedanib
    5d
    Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial. (PubMed, Lancet Oncol)
    Overall, GHS and quality of life were maintained for both treatment groups, with prespecified PRO variables favouring trastuzumab deruxtecan over treatment of physician's choice, suggesting that despite a longer treatment duration, there was no detrimental impact on patient health-related quality of life with trastuzumab deruxtecan. When considered with efficacy and safety data from DESTINY-Breast02, these results support the overall benefit of trastuzumab deruxtecan for patients with HER2-positive unresectable or metastatic breast cancer previously treated with trastuzumab emtansine.
    Clinical • P3 data • Clinical Trial,Phase III • Journal • Patient reported outcomes • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    lapatinib • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine
    6d
    CRITICS-II: Multicentric Randomised Trial for Resectable Gastric Cancer (clinicaltrials.gov)
    P2, N=207, Active, not recruiting, The Netherlands Cancer Institute | Recruiting --> Active, not recruiting | Trial completion date: Jul 2029 --> Mar 2029 | Trial primary completion date: Jul 2024 --> Apr 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Surgery
    |
    carboplatin • paclitaxel • docetaxel • capecitabine • oxaliplatin
    6d
    MAIBE: Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer (clinicaltrials.gov)
    P2, N=47, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    capecitabine
    6d
    SGNTUC 024: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Seagen Inc. | N=120 --> 40 | Trial primary completion date: May 2024 --> Mar 2025
    Enrollment change • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • 5-fluorouracil • capecitabine • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium
    7d
    Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (clinicaltrials.gov)
    P3, N=1530, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial • Combination therapy • Surgery
    |
    Keytruda (pembrolizumab) • capecitabine • sacituzumab tirumotecan (MK-2870)
    7d
    A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2025 --> Nov 2024
    Enrollment closed • Trial primary completion date • Combination therapy • Metastases
    |
    SIRPA (Signal Regulatory Protein Alpha)
    |
    Erbitux (cetuximab) • paclitaxel • docetaxel • capecitabine • ezabenlimab (BI 754091) • BI 765063 • BI 836880
    7d
    Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer (clinicaltrials.gov)
    P1, N=3, Terminated, National Cancer Institute (NCI) | Active, not recruiting --> Terminated; Due to Covid and poor enrollment
    Trial termination • Surgery • Metastases
    |
    capecitabine • oxaliplatin • leucovorin calcium • Imlygic (talimogene laherparepvec) • fluorouracil topical
    8d
    CAPOX + Bevacizumab + Tirelizumab Treating PDL1 CPS < 5 GEA (clinicaltrials.gov)
    P2, N=30, Recruiting, Chinese PLA General Hospital | Trial completion date: Oct 2023 --> Jun 2025 | Trial primary completion date: Apr 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab) • capecitabine • oxaliplatin
    8d
    Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study (clinicaltrials.gov)
    P2, N=46, Not yet recruiting, Fudan University
    New P2 trial
    |
    Tevimbra (tislelizumab) • capecitabine • oxaliplatin
    8d
    Capecitabine-induced severe adverse events-therapeutic drug monitoring and DPYD-gene analysis are recommended. (PubMed, BMJ Case Rep)
    Guidelines in various European countries recommend pretherapeutic DPYD genotyping, whereas it is not recommended by the National Comprehensive Cancer Network in the USA. Irrespective of DPYD genotyping, strict therapeutic drug monitoring is highly recommended to reduce the incidence and severity of adverse events.
    Journal • Adverse events
    |
    DPYD (Dihydropyrimidine Dehydrogenase)
    |
    capecitabine
    9d
    Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer (clinicaltrials.gov)
    P4, N=488, Not yet recruiting, Health Science Center of Xi'an Jiaotong University
    New P4 trial
    |
    capecitabine
    12d
    A Case of Stage Ⅳ Gastric Cancer with Multiple Liver Metastases, Resected Primary Tumor after Chemotherapy, and Alive for 3.5 Years without Recurrence (PubMed, Gan To Kagaku Ryoho)
    Six courses of capecitabine plus cisplatin plus trastuzumab(XP plus Tmab)therapy and 17 courses of capecitabine plus trastuzumab(X plus Tmab)therapy were performed. Six courses of X plus Tmab were administered as postoperative adjuvant chemotherapy, but were discontinued at the patient's request. Currently, 5 years have passed since the first chemotherapy and 3.5 years have passed since the surgery, and the patient is alive without recurrence, suggesting that the conversion surgery may have contributed to the prolonged survival.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • cisplatin • capecitabine
    12d
    Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data (PubMed, Zhonghua Wei Chang Wai Ke Za Zhi)
    Of them, 85 received pembrolizumab, 10 received sintilimab, 8 received tislelizumab, 4 received camrelizumab, 2 received toripalimab, and 1 received pabocizumab. The adjuvant chemotherapy regimens used among the chemotherapy alone group includes SOX regimen (132 cases), XELOX (102 cases), S-1 monotherapy (44 cases), and other regimens (15 cases)...Subgroup analysis showed that stage IIIC (HR=0.416, 95%CI: 0.184~0.940), aged ≥60 years (HR=0.336, 95%CI: 0.121~0.934) and extranodal invasion (HR=0.378, 95%CI: 0.170~0.839) were associated with benefit from the combined immune adjuvant chemotherapy, while no association was observed for MMR, HER-2 or EBER status. Stage III gastric/esophagogastric junction cancer patients may benefite from postoperative immune checkpoint inhibitor combined with adjuvant chemotherapy in real-world settings.
    Retrospective data • Journal • Checkpoint inhibition • Real-world evidence • Real-world
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-1 (Programmed cell death 1)
    |
    HER-2 positive • MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab) • capecitabine • oxaliplatin
    12d
    SHR-A1904-301: SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=924, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    capecitabine • oxaliplatin • SHR-A1904 • adebrelimab (SHR-1316)
    12d
    Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary (clinicaltrials.gov)
    P1, N=1, Terminated, Abramson Cancer Center at Penn Medicine | Active, not recruiting --> Terminated; failure to accrue
    Trial termination • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • capecitabine
    12d
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response (clinicaltrials.gov)
    P3, N=593, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open • Head-to-Head
    |
    cisplatin • gemcitabine • AiRuiKa (camrelizumab) • capecitabine
    13d
    Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) (clinicaltrials.gov)
    P2, N=531, Recruiting, AstraZeneca | Trial completion date: Mar 2025 --> Aug 2026 | Trial primary completion date: Mar 2025 --> Aug 2026
    Trial completion date • Trial primary completion date • Combination therapy • Pan tumor • Metastases
    |
    Avastin (bevacizumab) • carboplatin • Imfinzi (durvalumab) • 5-fluorouracil • capecitabine • leucovorin calcium • datopotamab deruxtecan (DS-1062a) • saruparib (AZD5305) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    13d
    Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients (clinicaltrials.gov)
    P2, N=39, Recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial • Metastases
    |
    Tyvyt (sintilimab) • Lenvima (lenvatinib) • capecitabine • oxaliplatin
    13d
    A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P3, N=378, Not yet recruiting, Shanghai Escugen Biotechnology Co., Ltd
    New P3 trial • Metastases
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • ESG401
    14d
    A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=436, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P3 trial • Metastases
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • izalontamab brengitecan (BL-B01D1)
    14d
    Brazilin Actuates Ferroptosis in Breast Cancer Cells via p53/SLC7A11/GPX4 Signaling Pathway. (PubMed, Chin J Integr Med)
    Brazilin actuated ferroptosis in breast cancer cells, and the underlying mechanism is mainly associated with the p53/SLC7A11/GPX4 signaling pathway.
    Journal
    |
    TP53 (Tumor protein P53) • GPX4 (Glutathione Peroxidase 4) • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) • SLC7A11 (Solute Carrier Family 7 Member 11)
    |
    TP53 expression • GPX4 expression
    |
    capecitabine • erastin
    15d
    PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2021 --> Apr 2024
    Enrollment closed • Trial primary completion date • Metastases
    |
    MSI (Microsatellite instability) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    MSI-H/dMMR
    |
    Loqtorzi (toripalimab-tpzi) • capecitabine • oxaliplatin
    15d
    CHINOREC: Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer (clinicaltrials.gov)
    P2, N=80, Completed, Johannes Laengle, MD, PhD | Recruiting --> Completed | Trial completion date: Dec 2024 --> Mar 2024 | Trial primary completion date: Jun 2024 --> Mar 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • capecitabine
    16d
    The Safety and Effectiveness of Bevacizumab in Metastatic Colorectal Cancer With Unresectable Metastases: A Real-Life Study From the South of Morocco. (PubMed, Cureus)
    In the first line, all patients received bi-chemotherapy plus bevacizumab, i.e., fluorouracil, oxaliplatin, and leucovorin in 34 (20.9%) patients; capecitabine plus oxaliplatin in 88 (54.3%) patients; leucovorin, fluorouracil, and irinotecan in 17 (10.4%) patients; and capecitabine plus irinotecan in 23 (14.1%) patients. With the new healthcare and social security systems, easier access to expensive treatments and molecular pathology tests is currently available. It is important to highlight that real-world data can offer valuable insights into the daily clinical practice of medical oncology.
    Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    16d
    Chemotherapeutic potential of betanin/capecitabine combination targeting colon cancer: experimental and bioinformatic studies exploring NFκB and cyclin D1 interplay. (PubMed, Front Pharmacol)
    These pathologic manifestations were reduced remarkably in betanin/capecitabine group. Collectively, our findings demonstrated the usefulness of betanin/capecitabine combination in targeting colon cancer and highlighted that betanin is a promising adjuvant therapy to capecitabine in treating colon cancer patients.
    Journal
    |
    CCND1 (Cyclin D1) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • IL1B (Interleukin 1, beta)
    |
    CCND1 expression
    |
    capecitabine
    19d
    Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=144, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial • Combination therapy • Metastases
    |
    paclitaxel • docetaxel • capecitabine • Kisqali (ribociclib)
    19d
    Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Convalife (Shanghai) Co., Ltd.
    New P2 trial • Metastases
    |
    Nerlynx (neratinib) • capecitabine
    19d
    FORTITUDE-103: A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. (clinicaltrials.gov)
    P1, N=80, Recruiting, Amgen | Trial primary completion date: Nov 2026 --> Mar 2026
    Trial primary completion date • Combination therapy • Metastases
    |
    FGFR2 overexpression • FGFR2b overexpression
    |
    Opdivo (nivolumab) • capecitabine • oxaliplatin • bemarituzumab (AMG 552)
    19d
    Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Henry Ford Health System | Initiation date: Feb 2024 --> Jun 2024
    Trial initiation date • Combination therapy • Metastases
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    capecitabine • Trodelvy (sacituzumab govitecan-hziy)
    19d
    NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer (clinicaltrials.gov)
    P2, N=200, Recruiting, Seoul National University Hospital | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    gemcitabine • 5-fluorouracil • capecitabine • leucovorin calcium • Onivyde (nanoliposomal irinotecan)
    19d
    IRB-2024-311: Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment. (clinicaltrials.gov)
    P2, N=134, Not yet recruiting, Xiangdong Cheng
    New P2 trial • Combination therapy • Metastases
    |
    Tevimbra (tislelizumab) • capecitabine • oxaliplatin
    20d
    Comparative efficacy and safety of targeted therapy and immunotherapy for HER2-positive breast cancer: a systematic review and network meta-analyses. (PubMed, Front Oncol)
    In terms of OS, Capecitabine+Trastuzumab, Lapatinib+Trastuzumab and Pyrotinib+Capecitabine exhibited better effect compared to other treatments. Based on these findings, trastuzumab-containing regimens emerge as a preferable and recommended choice in clinical practice for managing HER2-positive breast cancer. PROSPERO, identifier CRD42023414348.
    Review
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • EGFR positive
    |
    Herceptin (trastuzumab) • lapatinib • capecitabine • Irene (pyrotinib)
    20d
    Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients (clinicaltrials.gov)
    P=N/A, N=597, Completed, Sun Yat-sen University
    New trial • Real-world evidence • Real-world • Metastases
    |
    capecitabine • cyclophosphamide • vinorelbine tartrate
    20d
    Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis (clinicaltrials.gov)
    P1/2, N=138, Not yet recruiting, Washington University School of Medicine
    New P1/2 trial • Combination therapy
    |
    capecitabine • Prolia (denosumab) • zoledronic acid • zunsemetinib (ATI-450)
    20d
    PATRICIA: Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=73, Completed, SOLTI Breast Cancer Research Group | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    HER-2 positive • HR positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    Herceptin (trastuzumab) • Ibrance (palbociclib) • tamoxifen • Kadcyla (ado-trastuzumab emtansine) • capecitabine • fulvestrant • Halaven (eribulin mesylate) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)